Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Equipment
  3. tumor immune
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads

Refine by

Tumor Immune Equipment & Supplies

91 equipment items found

Myeloid - In Vivo Myeloid Programming with mRNA

Myeloid - In Vivo Myeloid Programming with mRNA

by:Myeloid Therapeutics   based inCambridge, MASSACHUSETTS (USA)
Myeloid’s novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this approach, Myeloid demonstrates that delivery of lipid-nanoparticles (LNPs) encapsulating mRNA results in uptake and selective expression by myeloid cells in vivo, leading to potent tumor killing in multiple cold tumor models. These data ...
CONTACT SUPPLIER

Oncolytic Virotherapy

Oncolytic Virotherapy

by:Fusix Biotech   based inMünchen, GERMANY
As multi-mechanistic antitumor agents, oncolytic viruses are emerging to be potent immunotherapeutic treatment options in different tumor indications. Oncoytic viruses specifically replicate in tumor cells due to altered signalling pathways supporting the tumor’s immune esape, leaving open replication advantages for viruses susceptible to intact signaling pathways. ...
CONTACT SUPPLIER

Boston - Model BOS-342 - Bispecific Antibody

Boston - Model BOS-342 - Bispecific Antibody

Manufactured by:Boston Pharmaceuticals   based inCambridge, MASSACHUSETTS (USA)
BOS-342 is a bispecific antibody comprised of an anti-GPC3 antagonistic antibody linked to a 4-1BB (CD137) agonistic anticalin ...
CONTACT SUPPLIER

Tonix - Model TNX-1700 - Gastric and Colorectal Cancers Antibody

Tonix - Model TNX-1700 - Gastric and Colorectal Cancers Antibody

Manufactured by:Tonix Pharmaceuticals Holding Corp.   based inChatham, NEW JERSEY (USA)
TNX-1700 is a stabilized recombinant version of Trefoil Factor 2 (TFF2) and is being developed by Tonix as a biologic to treat gastric and colorectal cancers. TFF2 is a small, secreted protein, encoded by the TFF2 gene in humans that is expressed in gastrointestinal mucosa where it functions to protect and repair mucosa. TFF2 is also expressed at low levels in splenic immune cells and is now ...
CONTACT SUPPLIER

Model OGB23501 - Tri-Specific Tumor Microenvironment (TME)

Model OGB23501 - Tri-Specific Tumor Microenvironment (TME)

by:Onegene Biotechnology   based inSuwon, SOUTH KOREA
OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, HCC, and renal ...
CONTACT SUPPLIER

Biomatik - Model RPU40018-50ug - Recombinant a Disintegrin and Metalloprotease 9 (ADAM9)

Biomatik - Model RPU40018-50ug - Recombinant a Disintegrin and Metalloprotease 9 (ADAM9)

Manufactured by:Biomatik Corporation   based inKitchener, ONTARIO (CANADA)
Species:Homo sapiens (Human). Source:E.coli. Tag Info:N-terminal His Tag. Biological Activity:Not tested. Covid-19: ...
CONTACT SUPPLIER

Alomfilimab - Model SAR445256 (Formerly KY1044) - Anti-ICOS Monoclonal Antibody

Alomfilimab - Model SAR445256 (Formerly KY1044) - Anti-ICOS Monoclonal Antibody

Manufactured by:Kiadis Pharma NV   based inAmsterdam, NETHERLANDS
Alomfilimab SAR445256 (formerly KY1044) is a human monoclonal IgG1 that selectively binds to Inducible T cell CO-stimulator (ICOS), a protein expressed at high levels on immunosuppressive regulatory T cells and at lower levels on effector T cells. Alomfilimab is designed to exert anti-tumour activity through preferential depletion of intra-tumoral regulatory T cells and stimulation (agonism) of ...
CONTACT SUPPLIER

BriaCell - Model Bria-IMT - Immunotherapy

BriaCell - Model Bria-IMT - Immunotherapy

Manufactured by:BriaCell Therapeutics Corp.   based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that directly stimulates the body’s own cancer fighting cells to attack and destroy breast cancer tumors. ...
CONTACT SUPPLIER

Genmab DuoBody - Model PD-L1x4-1BB (GEN1046) - Proprietary Bispecific Antibody

Genmab DuoBody - Model PD-L1x4-1BB (GEN1046) - Proprietary Bispecific Antibody

by:Genmab A/S    based inCopenhagen V, DENMARK
DuoBody PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed by Genmab under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. DuoBody®-PD-L1x4-1BB is designed to elicit an anti-tumor immune response by simultaneous ...
CONTACT SUPPLIER

FUSIX Technology

FUSIX Technology

by:Fusix Biotech   based inMünchen, GERMANY
The FUSIX Technology relies on a fusion-based oncolytic virus platform. Below you can see FUB101 in action. In this timelapse video FUB101 is killing a monolayer of cancer cells (HCC) within 48 hours through a fusogenic mechanism of action. The FUSIX technology is based on a hybrid virus construct combining all the advantages of both parental platforms while minimizing risks factors. This ...
CONTACT SUPPLIER

Beta-glucan - Glucan Molecular Structure

Beta-glucan - Glucan Molecular Structure

Manufactured by:Newgen Biotech(Ningbo) Co.,Ltd   based inXiangshan County, CHINA
Catering: yogurt, sports and nutrition bars, dietary substitutes, cereals, snacks, baked goods, etc. Beverages: Juices for smoothies, enhanced waters, sports and energy drinks, nutritional drinks, milk and dairy products. Supplements: capsules and tablets, soft candy and chewable tablets, powdered mixture. Pills, effervescent agents, granules, etc. Others: functional food granules, tablet foods, ...
CONTACT SUPPLIER

mRNA Cell Therapy Technology

mRNA Cell Therapy Technology

by:Myeloid Therapeutics   based inCambridge, MASSACHUSETTS (USA)
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ATAK cell therapy candidates through a rapid, single-day cell process. This method provides significant advantages to the patient, contract development, and manufacturing organizations ...
CONTACT SUPPLIER

Gexscope - Single Cell V(D)J Kit

Gexscope - Single Cell V(D)J Kit

Manufactured by:Singleron Biotechnologies GmbH   based inKöln, GERMANY
GEXSCOPE Single Cell V(D)J Kit enables simultaneous detection of T-cell or B-cell receptor gene expression, together with whole transcriptome expression at single-cell ...
CONTACT SUPPLIER

PepSup - Cell Activation Kit

PepSup - Cell Activation Kit

Manufactured by:JPT Peptide Technologies GmbH   based inBerlin, GERMANY
PepSup is a highly standardized, peptide-based cell activation (cell stimulation) assay designed to produce short-term culture supernatants for analysis of cytokines or other mediators of interest. We create your PepSup Cell Activation Kit with your choice of PepMix Peptide Pools Antigen Peptides or custom peptides using a specialized culture medium. A PepSup kit contains sufficient reagents for ...
CONTACT SUPPLIER

AvidiMab - Antibodies for Cancer

AvidiMab - Antibodies for Cancer

Manufactured by:Scancell   based inOxford, UNITED KINGDOM
During the development of the anti-glycan monoclonal antibodies (mAbs), Scancell identified unique sequence residues in the Fc region that enable mAbs to self-associate upon target recognition, resulting in more potent, high avidity ...
CONTACT SUPPLIER

Myeloid - Model MT-302 (TROP2-FcA LNP) - In Vivo Programming Pipeline

Myeloid - Model MT-302 (TROP2-FcA LNP) - In Vivo Programming Pipeline

by:Myeloid Therapeutics   based inCambridge, MASSACHUSETTS (USA)
Emerging from the Company’s proprietary ATAK™ CAR receptor library, Myeloid’s novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this approach, Myeloid demonstrates that delivery of lipid-nanoparticles (LNPs) encapsulating mRNA results in uptake and selective expression by myeloid cells in ...
CONTACT SUPPLIER

Txinno Bioscience - Model ENPP1 - Emopamil-Binding Protein (EBP) Inhibitor

Txinno Bioscience - Model ENPP1 - Emopamil-Binding Protein (EBP) Inhibitor

Manufactured by:TxinnoBioscience Inc.   based inYongin-si, SOUTH KOREA
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), is a type II transmembrane protein with nucleotide pyrophosphatase and phosphodiesterase enzymatic activities. Recently, ENPP1 has been found to play an important role in regulating STING pathway. By hydrolyzing cGAMP (natural ligand of STING) into AMP and GMP, ENPP1 negatively regulates STING-mediated type I interferon production and ...
CONTACT SUPPLIER

Tulmimetostat - Model CPI-0209 - Second-Generation EZH2 Inhibitor

Tulmimetostat - Model CPI-0209 - Second-Generation EZH2 Inhibitor

Manufactured by:MorphoSys AG   based inPlanegg, GERMANY
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes ...
CONTACT SUPPLIER

Boston - Model BOS-371 - Potent Monoclonal Antibody

Boston - Model BOS-371 - Potent Monoclonal Antibody

Manufactured by:Boston Pharmaceuticals   based inCambridge, MASSACHUSETTS (USA)
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
CONTACT SUPPLIER

Immune-Onc - Model IO-108 - (Anti-LILRB2) Mechanisms of Action Program

Immune-Onc - Model IO-108 - (Anti-LILRB2) Mechanisms of Action Program

Manufactured by:Immune-Onc Therapeutics, Inc.   based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin clinical trials with IO-108 in the second half of ...
CONTACT SUPPLIER
  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT